What’s New in MS Research: March 2021

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article FDA approves Ponvory™ for the treatment of relapsing forms of MS Plegridy® now approved for intramuscular injection Biotech company prepares Phase II trial of potential oral MS therapy Assessing Ocrevus® in older adults with progressive MS Beneficial effects of Ponvory™ on fatigue […]

Read News Article

FDA Approves Ponvory for the Treatment of Relapsing Forms of MS

Updated: March 25, 2021 to include patient assistance resource information Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the United States Food and Drug Administration (FDA) approved Ponvory™ (ponesimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults – including […]

Read News Article

The Multiple Sclerosis Association of America (MSAA) Focuses on Improving Mental Health and Wellness in Honor of MS Awareness Month

The Multiple Sclerosis Association of America (MSAA) recognizes March as Multiple Sclerosis (MS) Awareness Month. MSAA is proud to announce the 2021 awareness campaign theme on Improving Mental Health and Wellness, with specific programs addressing Purpose in Life, depression and anxiety in MS, care partnering, and wellness strategies to improve symptom management and overall quality […]

Read News Article

What’s New in MS Research: January 2021

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article FDA approves shorter infusion time for Ocrevus® (ocrelizumab) Positive topline results from two studies of ublituximab Biotin for progressive MS: Only modest benefit vs. placebo in Phase III trial Two Phase III studies seeking to enroll participants with progressive MS Examining the […]

Read News Article

Impact Education, LLC and MSAA Release New Whitepaper on Payer Considerations for Providing Support to People With MS and Their Care Partners

BLUE BELL, Pa.–(BUSINESS WIRE)–Impact Education, LLC (IMPACT) and the Multiple Sclerosis Association of America (MSAA) announce the release of a new whitepaper based on key findings from a series of dynamic roundtable discussions between payers and multiple sclerosis (MS) healthcare providers. MS affects about 1,000,000 people in the United States and while quality care is […]

Read News Article

What’s New in MS Research: November 2020

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Studies with Approved Disease-Modifying Therapies Experimental Disease-Modifying Therapies MS Diagnosis, Course, and Impact Specific Patient Populations Other Interventions For More Information Introduction While we all know “MS” stands for “multiple sclerosis,” with so much exciting research reported in this edition of “What’s […]

Read News Article

What’s New in MS Research: September 2020

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Evobrutinib shows efficacy up to 108 weeks in open-label extension study Government study evaluating Rebif® (interferon beta-1a) as COVID-19 treatment Stem cell therapy for MS: Examining the impact on cognition The primary factor shaping patients’ treatment choices Why taking your disease-modifying therapy […]

Read News Article

FDA Approves Kesimpta® (Ofatumumab), the First Self-Administered B-cell Therapy for Relapsing Forms of MS

Updated September 3, 2020 Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD On August 20, 2020, Novartis announced that the United States Food and Drug Administration (FDA) approved Kesimpta® (ofatumumab) for adults with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease. Kesimpta is a […]

Read News Article

FDA Approves Generic Version of Tecfidera®, Taken Orally for MS

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD On August 17, 2020, the United States Food and Drug Administration (FDA) awarded early approval of Mylan’s generic version of Biogen’s Tecfidera® (dimethyl fumarate), an oral medication approved in 2013 for relapsing forms of MS in adults. Mylan announced the launch of this generic medication […]

Read News Article

MSAA’s Publications, Website, and Blog Receive National Recognition

The Multiple Sclerosis Association of America (MSAA) is proud to announce that many of our free publications and resources received awards this summer from the APEX Awards for Publication Excellence, the Digital Health Awards, the National Health Information Awards, and Healthline! MSAA received four Awards of Excellence from the Thirty-Second Annual APEX Awards! The first […]

Read News Article